Skip to content

Clinical observation for the effect of nalbuphine and fentanyl on gastrointestinal function of postoperative patients admitted to ICU

Clinical observation for the effect of nalbuphine and fentanyl on gastrointestinal function of postoperative patients admitted to ICU

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900025096
Enrollment
Unknown
Registered
2019-08-10
Start date
2019-10-01
Completion date
Unknown
Last updated
2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

critically ill patients

Interventions

Nabuffine group:Nabuffine

Sponsors

The First Affiliated Hospital of Air Force Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Surgical patients; 2. CPOT score >=3 points; 3. Aged 18 to 75 years; 4. The ICU stay time is expected to be >=48h; 5. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients who need cardiopulmonary resuscitation, or have abnormal ventilation function (abnormal ventilator function, decreased respiratory driving force, increased airway resistance or airway obstruction), or abnormal oxygenation. 2. Apache II score >=23. 3. Suffering from esophageal reflux disease, severe gastrointestinal injury AGI score >=3 points. 4. Long-term use of benzodiazepine sedatives and opioid analgesics. 5. Delirium and alcohol withdrawal symptoms exist. 6. Severe liver dysfunction (Child-Pugh Grade C). 7. Bronchial asthma or COPD, myasthenia gravis patients. 8. Severe brain injury, brain tumor, intracranial hypertension and other patients prone to respiratory depression. 9. Patients who have been selected for other clinical trials. 10. Study drug allergy or other taboos. 11. Pregnant or lactating women. 12. Patients themselves or their legal authorized representatives are not willing to provide informed consent. 13. There are factors that increase the risks associated with participating in the study (such as severe hypotension) or potential disputes. According to the judgment of the researchers, they are not suitable for inclusion in the study.

Design outcomes

Primary

MeasureTime frame
First defecation or exhaust time;

Secondary

MeasureTime frame
The time of first eating;the number of nausea and vomiting within 48 hours;AGI score;the use of gastrointestinal motility drugs;Dosage and adjustment times of analgesic and sedative drugs;Spending during ICU;length of hospital stay;short-term mortality rate;Biochemical indexes;SOFA Score;APACHE II Score;Basic vital signs;

Countries

China

Contacts

Public ContactZhang Xijing

The First Affiliated Hospital of Air Force Military Medical University

zhangxj918@163.com+86 029 84775344

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026